David Harold Drewry

The paper maps the chemokine-stimulated signal transduction network in monocytic cells and shows that chemotaxis emerges from a divergent signaling network that can be inhibited to block cell migration.

The paper compares cell-free and cellular assays for kinase inhibitor selectivity, finding divergent results and identifying new kinase interactions in cells.

This paper identifies NUAK2 as a therapeutic target in AR-indifferent prostate cancer, showing trilaciclib inhibits NUAK2 and suppresses tumor growth.

The paper identifies structure-activity relationships for diarylpyrazole inhibitors of the fungal kinase Yck2, showing improved selectivity and antifungal activity.

The paper uses chemoproteomic profiling to identify selective anti-fungal kinase inhibitors targeting C. albicans CK1 homologs.

The paper identifies and characterizes a chemical probe for CDKL2, demonstrating its selectivity and biological impact in neurons and cancer cells.

This study determines the structure of human brachyury, identifies DNA binding insights and a G177D variant, and discovers small molecule binders for potential cancer therapy.

The paper identifies and optimizes narrow-spectrum TLK2 inhibitors using QSAR analysis and structural studies.

The paper develops specific CDKL5 inhibitors that do not affect GSK3β activity and shows their effects on synaptic function and LTP in rat hippocampal slices.

The paper discusses the potential of kinase inhibitors for neurodegenerative diseases, highlighting the need for validated targets and strategies for drug discovery.